Glutamate Induced Molecular Events

谷氨酸诱导的分子事件

基本信息

项目摘要

DESCRIPTION (provided by applicant): Our exciting experimental data generated over the last several years indicate the novel role that glutamate receptor mediated neurogenic events play as a key factor in inflammatory nociceptive processes. Glutamate receptor antagonists given in the spinal cord dorsal horn eliminate half of the joint swelling induced in rat inflammation models. Our recent finding that knee injections of glutamate receptor agonists increase joint blood flow, plasma/protein extravasation, joint swelling, and nerve activation intimates peripheral glutamate involvement. This may account for glutamate increases in inflamed joints in animal models and in clinic patients with active arthritis. In clinical samples, glutamate is high in joints with active arthritis and is independent of levels in the patients' other joints or in the plasma. Preliminary data presented here for an in vitro model suggest that glutamate release by small, nociceptive afferent fibers in the knee joint can directly initiate inflammatory cascades through stimulation of tumor necrosis factor (TNF_alpha) release since specific glutamate agonists added to synovial cell cultures increase TNF_alpha levels detected in the culture supernatant. Secondly, the observation that the NMDA glutamate receptor subunit NR1 can translocate to the nucleus in both the in vitro and in vivo models suggests that a novel signal transduction event may be involved. Together these findings led to the hypothesis for the studies proposed that glutamate receptor_mediated molecular events play a critical role in initiation of inflammatory cascades. Specific Aims designed for these studies include the following: Specific Aim 1. To determine if the NMDA glutamate receptor subunit NR1 can translocate to the nucleus. Specific Aim 2. To identify key signaling pathways regulating nuclear translocation of NMDA glutamate receptor subunit NR1. Specific Aim 3. To determine if the nuclear NR I translocation is associated with glutamate_induced TNF_cc release from synoviocytes. These studies will seek mechanisms that may lead to novel translational approaches to abrogation of the inflammatory state through pharmacological interventions directed at inducible, glutamate receptor_mediated signal transduction pathways since use of glutamate receptor antagonists is not a clinical option. These studies will utilize anatomical, biochemical, and molecular methods to examine models of arthritis in rats and human clonal, synovial cultures. Since case studies in the literature report recovery of joint integrity in some cases after stroke, these studies seek a better understanding of the interactions of neurogenic and immune processes in the hope that reversal of joint inflammation for patients is possible.
描述(由申请人提供):我们产生了令人兴奋的实验数据

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KARIN N. WESTLUND-HIGH其他文献

KARIN N. WESTLUND-HIGH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KARIN N. WESTLUND-HIGH', 18)}}的其他基金

Advancing Development of Novel Immunotherapy for Chemotherapy-induced Peripheral Neuropathy (CIPN)
推进化疗引起的周围神经病变 (CIPN) 的新型免疫疗法的发展
  • 批准号:
    10588384
  • 财政年份:
    2023
  • 资助金额:
    $ 7.45万
  • 项目类别:
ShEEP Request for Biotek Cytation 5 Imaging System
ShEEP 请求 Biotek Cytation 5 成像系统
  • 批准号:
    10175798
  • 财政年份:
    2020
  • 资助金额:
    $ 7.45万
  • 项目类别:
Modulating Pain Generators of Chronic Trigeminal Neuropathic Pain
调节慢性三叉神经病理性疼痛的疼痛发生器
  • 批准号:
    10513813
  • 财政年份:
    2016
  • 资助金额:
    $ 7.45万
  • 项目类别:
Peripheral and Central Pain Generators of Chronic Trigeminal Neuropathic Pain
慢性三叉神经病理性疼痛的周围和中枢疼痛发生器
  • 批准号:
    9031396
  • 财政年份:
    2016
  • 资助金额:
    $ 7.45万
  • 项目类别:
Modulating Pain Generators of Chronic Trigeminal Neuropathic Pain
调节慢性三叉神经病理性疼痛的疼痛发生器
  • 批准号:
    10293538
  • 财政年份:
    2016
  • 资助金额:
    $ 7.45万
  • 项目类别:
Modulating Pain Generators of Chronic Trigeminal Neuropathic Pain
调节慢性三叉神经病理性疼痛的疼痛发生器
  • 批准号:
    10012520
  • 财政年份:
    2016
  • 资助金额:
    $ 7.45万
  • 项目类别:
Physiological and Emotional Reactivity to Pain after Physical and Sexual Abuse
身体和性虐待后对疼痛的生理和情感反应
  • 批准号:
    8214456
  • 财政年份:
    2011
  • 资助金额:
    $ 7.45万
  • 项目类别:
Glutamate Induced Molecular Events Contributing to Chro*
谷氨酸诱导的分子事件有助于 Chro*
  • 批准号:
    6533040
  • 财政年份:
    2001
  • 资助金额:
    $ 7.45万
  • 项目类别:
Neurogeneic Amplification of Pancreatitis Pain
胰腺炎疼痛的神经源性放大
  • 批准号:
    7871859
  • 财政年份:
    2000
  • 资助金额:
    $ 7.45万
  • 项目类别:
Neurogenic Amplification of Pancreatitis Pain
胰腺炎疼痛的神经源性放大
  • 批准号:
    8288067
  • 财政年份:
    2000
  • 资助金额:
    $ 7.45万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
  • 批准号:
    MR/Y009681/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.45万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.45万
  • 项目类别:
    Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
  • 批准号:
    10068495
  • 财政年份:
    2024
  • 资助金额:
    $ 7.45万
  • 项目类别:
    Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 7.45万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
  • 批准号:
    24K19850
  • 财政年份:
    2024
  • 资助金额:
    $ 7.45万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
  • 批准号:
    491810
  • 财政年份:
    2023
  • 资助金额:
    $ 7.45万
  • 项目类别:
    Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
  • 批准号:
    489316
  • 财政年份:
    2023
  • 资助金额:
    $ 7.45万
  • 项目类别:
    Operating Grants
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
  • 批准号:
    EP/Y027760/1
  • 财政年份:
    2023
  • 资助金额:
    $ 7.45万
  • 项目类别:
    Fellowship
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
  • 批准号:
    23K14987
  • 财政年份:
    2023
  • 资助金额:
    $ 7.45万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
  • 批准号:
    10696749
  • 财政年份:
    2023
  • 资助金额:
    $ 7.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了